1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
NanoenTek, Inc.

NanoenTek, Inc.

KKRX:039860
4,590.00
KRW
+100.00
(+2.23%)
78.15EPS
66.28P/E
196.03BMarket Cap
NanoenTek, Inc.
KRX:039860
(Korea Stock Exchange)

Recent

price

4,590.00

P/E

ratio

66.28

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
855.61
691.2
689.64
972.19
894.22
1,071.03
910.81
976.66
1,005.91
1,000.01
1,108.22
1,335.35
1,312.98
999.6
1,010.99
1,134.11
1,197.69
Revenue per Share
-386
-641.22
-302
-63
-113
-314
-607
-85
129
219
103
273.18
174
-137
119
47
78.15
Basic EPS, GAAP
-362.7
-358.21
-561.3
-67.77
-190
-376.42
-295.88
-9.22
0.42
82.59
150.76
238.62
131.41
-73.78
-157.06
60.57
138.86
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,595.18
1,477.58
1,180.94
1,193.28
1,572.9
1,578.1
1,046.59
969.87
1,336.88
1,546.23
1,697.51
1,952.98
2,150.46
1,999.17
2,304.4
2,404.07
2,432.1
Book Value per Share
1,513.67
1,374
933.16
844.01
1,215.2
1,067.84
760.41
746.16
1,138.03
1,380.07
1,564.96
1,890.15
2,081.59
1,945.69
2,220.34
2,324.43
2,348.51
Tangible Book Value per Share
18
19
19
20
22
23
24
24
26
26
27
27
27
27
30
34
34
Basic Weighted Avg Shares
15,096
13,154
13,435
19,084
19,499
24,839
22,206
23,810
25,797
26,256
29,443
35,784
35,201
26,837
30,464
38,130
40,658
Sales/Revenue/Turnover
-10.67
-67.51
-39.66
-2.48
-13.29
-29.03
-43.62
7.02
10.95
11.62
11.56
14.63
12.45
-8.31
2.04
2.89
2.88
Operating Margin (%)
1,147
1,694
1,257
1,761
2,186
2,756
2,835
2,844
2,558
2,493
2,434
2,654
2,442
2,548
2,659
3,417
3,624
Depreciation Expense
-6,811
-12,203
-5,883
-1,237
-2,464
-7,282
-14,799
-2,072
3,308
5,750
2,737
7,321
4,665
-3,678
3,586
1,580
2,653
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
1.35
- -
- -
- -
15.31
- -
3.55
- -
- -
Effective Tax Rate (%)
-45.11
-92.77
-43.79
-6.48
-12.64
-29.32
-66.64
-8.7
12.82
21.9
9.29
20.46
13.25
-13.71
11.77
4.14
6.53
Profit Margin (%)
10,974
30,364
20,255
20,301
17,968
17,492
15,774
6,188
18,122
24,025
28,621
30,902
35,724
35,361
52,630
65,940
67,329
Working Capital
1,063
13,033
13,593
14,387
- -
3,080
12,287
- -
- -
37
461
376
292
91
79
1,233
1,117
LT Debt
28,153
28,748
22,977
23,578
35,502
38,408
25,577
23,731
35,150
41,026
45,487
52,341
57,649
53,593
73,994
90,979
92,039
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
8.55
- -
- -
- -
7.2
- -
1
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
9.52
- -
- -
- -
8.42
- -
5.6
- -
- -
Return on Capital (%)
-21.56
-42.89
-22.75
-5.31
-8.34
-19.71
-46.26
-8.41
11.24
15.1
6.33
14.97
8.48
-6.61
5.62
1.92
3.19
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
400
729
713
LT Borrowings
- -
- -
- -
LT Finance Leases
813
1,233
1,117
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
38
38
Market Capitalization
110,780
227,061
196,029

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
55,722
71,362
74,464
Cash, Cash Equivalents & STI
33,702
46,921
48,810
Accounts Receivable, Net
- -
9,415
9,324
Inventories
13,760
12,572
13,776
Total Current Liabilities
4,186
5,423
7,134
Payables & Accruals
- -
- -
- -
ST Debt
400
729
713
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.43%
15.84%
22.95%
Free Cash Flow
1,988.21%
-29.12%
-143.03%
Net Income, GAAP
-52.21%
-60.21%
-55.93%
Sales/Revenue/Turnover
5.37%
6.97%
25.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,586
6,715
7,912
9,251
30,464
2025
7,964
8,971
8,551
12,644
38,130
2026
10,491
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
21
18
-10
86.07
119
2025
12
-33.99
19.72
49.73
47
2026
37.97
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
NanoenTek, Inc. is a South Korea-based biotechnology and medical device company that develops, manufactures, and commercializes microfluidics- and lab-on-a-chip-based point-of-care in vitro diagnostic systems and life science research instruments. The company operates across two primary business segments: Life Science and In Vitro Diagnostics. Its core products and solutions include automated cell counters and live-cell imaging systems, comprising the EVE series of automated cell counters (EVE, EVE Plus, EVE-HT, and EVE-Auto), the JuLI series of real-time live-cell imaging and recording systems (JuLI Stage and JuLI FL), the Arthur image cytometer, and the C-Chip line of precision disposable hemocytometers; cell therapy quality control and cell analysis platforms, featuring the ADAM series of fluorescence cell counters, including the ADAM-MC2, ADAM-CellT for cell and gene therapy manufacturing processes, ADAM-CD34 for stem cell enumeration, and ADAM-rWBC for residual white blood cell analysis in blood transfusion products; point-of-care testing diagnostic platforms, anchored by the FREND System, a rapid microfluidic fluorescence immunoassay analyzer offering quantitative test cartridges for cardiac markers (Troponin I, CK-MB, and BNP), thyroid hormones (TSH and Free T4), cancer biomarkers (PSA and AFP), Vitamin D, testosterone, and infectious disease antigens; electroporation and transfection solutions, including the Neon transfection system designed for high-efficiency cellular gene delivery; and custom microfluidic plastic biochips and assay consumables manufactured through proprietary micro-machining and surface treatment technologies. NanoenTek serves clinical laboratories, hospitals, blood centers, academic research institutes, and biopharmaceutical manufacturers in more than 80 countries worldwide, supporting its international market presence through its United States subsidiary, NanoEnTek USA, Inc., located in Waltham, Massachusetts. In recent developments, the company underwent an ownership transition following the divestment of a controlling interest by SK Square, realigning its operational focus toward high-growth cell and gene therapy analytics and bioprocessing quality control. NanoenTek has expanded its commercial portfolio with advanced automated cell counting solutions, secured additional international regulatory clearances including European CE-IVDR certifications and United States FDA 510(k) clearances for its FREND and ADAM diagnostic lines, and broadened its global distribution partnerships across North America, Europe, and the Asia-Pacific region. Founded in 2000, NanoenTek, Inc. is headquartered in Seoul, South Korea.